Kevin Shannon, MD

Professor of Pediatrics
Children's Precision Medicine
Hidden

I am a physician-scientist whose research program focuses on hematopoietic growth control, genetic mechanisms underlying leukemogenesis, aberrant Ras signaling in human developmental disorders and cancer, mouse cancer modeling, and molecular therapeutics. I served as Director of the UCSF Medical Scientist Training Program (MSTP) from 2006-2012. I have been a research mentor for medical students, graduate students, and post-doctoral scholars, including six post-doctoral scholars who received “K” series awards from the NCI.

Publications: 

ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth.

Nature chemical biology

Remsberg JR, Suciu RM, Zambetti NA, Hanigan TW, Firestone AJ, Inguva A, Long A, Ngo N, Lum KM, Henry CL, Richardson SK, Predovic M, Huang B, Dix MM, Howell AR, Niphakis MJ, Shannon K, Cravatt BF

KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.

JCI insight

Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Del Pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, Sheppard D, Klein OD, Tuveson DA, Braun BS, Shannon K

Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.

Blood

Zambetti NA, Firestone AJ, Remsberg JR, Huang BJ, Wong JC, Long AM, Predovic M, Suciu RM, Inguva A, Kogan SC, Haigis KM, Cravatt BF, Shannon K

Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.

Leukemia

Wandler AM, Huang BJ, Craig JW, Hayes K, Yan H, Meyer LK, Scacchetti A, Monsalve G, Dail M, Li Q, Wong JC, Weinberg O, Hasserjian RP, Kogan SC, Jonsson P, Yamamoto K, Sampath D, Nakitandwe J, Downing JR, Zhang J, Aster JC, Taylor BS, Shannon K

Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.

The Journal of clinical investigation

Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML

Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Bhatia S, Chen Y, Wong FL, Hageman L, Smith K, Korf B, Cannon A, Leidy DJ, Paz A, Andress JE, Friedman GK, Metrock K, Neglia JP, Arnold M, Turcotte LM, de Blank P, Leisenring W, Armstrong GT, Robison LL, Clapp DW, Shannon K, Nakamura JL, Fisher MJ

Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.

PLoS genetics

Huang BJ, Wandler AM, Meyer LK, Dail M, Daemen A, Sampath D, Li Q, Wang X, Wong JC, Nakitandwe J, Downing JR, Zhang J, Taylor BS, Shannon K

High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

Cell reports

Mues M, Karra L, Romero-Moya D, Wandler A, Hangauer MJ, Ksionda O, Thus Y, Lindenbergh M, Shannon K, McManus MT, Roose JP

Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Cancer cell

Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, Solit DB, Shannon K, Chandarlapaty S, Berger MF, Taylor BS

Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes.

JCI insight

Wong JC, Bryant V, Lamprecht T, Ma J, Walsh M, Schwartz J, Del Pilar Alzamora M, Mullighan CG, Loh ML, Ribeiro R, Downing JR, Carroll WL, Davis J, Gold S, Rogers PC, Israels S, Yanofsky R, Shannon K, Klco JM

AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells.

Cell stem cell

Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT

Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.

PloS one

Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.

Cancer research

Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.

Cell

Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Nature medicine

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K

Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Sherborne AL, Lavergne V, Yu K, Lee L, Davidson PR, Mazor T, Smirnoff IV, Horvai AE, Loh M, DuBois SG, Goldsby RE, Neglia JP, Hammond S, Robison LL, Wustrack R, Costello JF, Nakamura AO, Shannon KM, Bhatia S, Nakamura JL

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Haematologica

Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM

KRAS insertion mutations are oncogenic and exhibit distinct functional properties.

Nature communications

White Y, Bagchi A, Van Ziffle J, Inguva A, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ

KRAS Engages AGO2 to Enhance Cellular Transformation.

Cell reports

Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey JA, Bollag G, Shannon K, Walter NG, Kumar-Sinha C, Chinnaiyan AM

Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.

eLife

Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K

Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.

Nature genetics

Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW

CCR4 drives ATLL jail break.

The Journal of experimental medicine

Shannon KM

Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Blood

Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q

NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.

Blood

Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA

Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.

Nature

Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K

A(nother) RAF mutation in LCH.

Blood

Shannon K, Hermiston M

MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.

Cancer cell

Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW

Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.

Blood

Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML

Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.

BMC cancer

North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD

PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.

Science signaling

Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K

Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

Nature

Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Clinical cancer research : an official journal of the American Association for Cancer Research

Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.

Blood

Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, Shannon K, Garcia PD

Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

Cancer discovery

Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.

Blood

Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM

Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.

Science signaling

Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, Chakraborty AK, Wabl M, Roose JP

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

The Journal of clinical investigation

Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Science translational medicine

Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS

Oncogenic Ras scales the ALPS.

Blood

Shannon K, Li Q

Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.

Blood

Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS

Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Cancer research

Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Blood

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K

Genetics, epigenetics, and leukemia.

The New England journal of medicine

Shannon K, Armstrong SA

Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia.

The Journal of experimental medicine

Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, Le Beau MM, Kogan SC

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.

Genes & development

Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW

Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies.

Blood

Wong JC, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, Alzamora P, Kogan SC, Akagi K, Wolff L, Le Beau MM, Killeen N, Shannon K

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.

Proceedings of the National Academy of Sciences of the United States of America

Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K

Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.

American journal of medical genetics. Part A

Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.

Nature

Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, Wolff L, Sebolt-Leopold J, Shannon K

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.

Blood

Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM

Oncogenic Kras initiates leukemia in hematopoietic stem cells.

PLoS biology

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS

Tumor suppressor gene inactivation in myeloid malignancies.

Best practice & research. Clinical haematology

Wong JC, Le Beau MM, Shannon K

Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Cancer cell

Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML

MLL5 contributes to hematopoietic stem cell fitness and homeostasis.

Blood

Zhang Y, Wong J, Klinger M, Tran MT, Shannon KM, Killeen N

Targeting Ras in myeloid leukemias.

Clinical cancer research : an official journal of the American Association for Cancer Research

Braun BS, Shannon K

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

Nature genetics

Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T

Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation.

Human mutation

Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, Devriendt K, Frijns JP, Rybin V, de Ravel TJ, Shannon K, Cools J, Scheffzek K, Legius E

Cancer: hay in a haystack.

Nature

Shannon KM, Le Beau MM

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.

Blood

Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, Alonzo TA

Biochemical and functional characterization of germ line KRAS mutations.

Molecular and cellular biology

Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM, Molven A, Shannon K

Targeting oncogenic Ras.

Genes & development

Diaz-Flores E, Shannon K

Hyperactive Ras in developmental disorders and cancer.

Nature reviews. Cancer

Schubbert S, Shannon K, Bollag G

Abnormal hematopoiesis in Gab2 mutant mice.

Blood

Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E, Rowe S, Qu CK, Tse W, Shannon KM, Bunting KD

Deregulated Ras signaling in developmental disorders: new tricks for an old dog.

Current opinion in genetics & development

Schubbert S, Bollag G, Shannon K

Sending out an SOS.

Nature genetics

Shannon K, Bollag G

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Blood

Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS

Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.

Blood

Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA

Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders.

Cell cycle (Georgetown, Tex.)

Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M

Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Blood

Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.

Pediatric blood & cancer

Lauchle JO, Braun BS, Loh ML, Shannon K

Harnessing preclinical mouse models to inform human clinical cancer trials.

The Journal of clinical investigation

Gutmann DH, Hunter-Schaedle K, Shannon KM

Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.

Blood

Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, Neuberg DS, Shannon KM, Sallan SE, Gilliland DG

Germline KRAS mutations cause Noonan syndrome.

Nature genetics

Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP

Therapy-induced malignant neoplasms in Nf1 mutant mice.

Cancer cell

Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

Blood

Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL

Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22.

Genomics

Curtiss NP, Bonifas JM, Lauchle JO, Balkman JD, Kratz CP, Emerling BM, Green ED, Le Beau MM, Shannon KM

JAKing up hematopoietic proliferation.

Cancer cell

Shannon K, Van Etten RA

Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells.

The Journal of experimental medicine

Katsumoto TR, Duda J, Kim A, Wardak Z, Dranoff G, Clapp DW, Shannon K

Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.

Blood

Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW, Shannon KM

RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.

Genes, chromosomes & cancer

Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA, Le Beau MM, Shannon KM

The sum is greater than the FGFR1 partner.

Cancer cell

Braun BS, Shannon K

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Blood

Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM

SHP-2 and myeloid malignancies.

Current opinion in hematology

Tartaglia M, Niemeyer CM, Shannon KM, Loh ML

Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Proceedings of the National Academy of Sciences of the United States of America

Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM

Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.

Blood

Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM

IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Proceedings of the National Academy of Sciences of the United States of America

Wong S, McLaughlin J, Cheng D, Shannon K, Robb L, Witte ON

Acute myeloid leukemia associated with t(8;21) or trisomy 8 in children with neurofibromatosis, type 1.

Journal of pediatric hematology/oncology

Kratz CP, Antonietti L, Shannon KM, Dole MG, Friebert SE

Mouse cancer models as a platform for performing preclinical therapeutic trials.

Current opinion in genetics & development

Weiss B, Shannon K

Acute leukemia: a pediatric perspective.

Cancer cell

Downing JR, Shannon KM

Testing of new agents in childhood cancer preclinical models: meeting summary.

Clinical cancer research : an official journal of the American Association for Cancer Research

Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA

Hematologic effects of inactivating the Ras processing enzyme Rce1.

Blood

Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM

MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia.

Oncogene

Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, Le Beau MM, Shannon KM

Ras processing as a therapeutic target in hematologic malignancies.

Current opinion in hematology

Le DT, Shannon KM

GTPase activating proteins: critical regulators of intracellular signaling.

Biochimica et biophysica acta

Donovan S, Shannon KM, Bollag G

Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor.

Blood

Kratz CP, Emerling BM, Bonifas J, Wang W, Green ED, Le Beau MM, Shannon KM